Background: Acetaminophen (paracetamol) is a widely used over-the-counter drug, but concerns of genotoxic effects have been raised. After we recently found an almost two-fold increased risk of hematologic malignancies associated with high use of acetaminophen in the prospective VITamins And Lifestyle (VITAL) study, we herein further examined the association between acetaminophen use and cancer risk in the VITAL cohort.
Introduction
Acetaminophen (paracetamol) is one of the most widely used over-the-counter analgesic antipyretics. However, as the active metabolite of phenacetin, which is considered carcinogenic to humans (1), significant genotoxic effects have long been a concern. This possibility has been investigated by a number of epidemiologic studies, primarily with case-control design, with inconsistent results (2) (3) (4) . Recently, we found an almost 2-fold increased risk of hematologic malignancies other than chronic lymphocytic leukemia/small lymphocytic lymphoma associated with high use of acetaminophen in the prospective VITamins and Lifestyle (VITAL) study (5) . We have now examined the association of acetaminophen use with incidence of total cancers and individual solid tumors in this cohort.
Methods

Study cohort
Details of the VITAL study have been published previously (6) . Among 77,719 men and women deemed eligible for study participation, 11,463 were excluded because of a prior history of any cancer other than nonmelanoma skin cancer or missing cancer information at baseline. We additionally excluded 3,394 participants with missing exposure information and 21 cases with postbaseline cancer on death certificate only without a diagnosis date, leaving 62,841 participants, aged 61.5 AE 7.3 (mean AE SD), available for study.
Data collection
Participants completed a baseline questionnaire on demographics, health history, cancer risk factors, diet, and medications that encompassed questions on regular use, defined as !1 d/wk for !1 years, of acetaminophen and other analgesics, including frequency and duration of use over the previous 10 years. Ten-year use was categorized as "no use," "low use" (<4 d/wk or <4 years), and "high use" (!4 d/wk and !4 years).
Case ascertainment
After a mean follow-up of 6.5 AE 1.7 years, a diagnosis of incident, invasive malignancy other than nonmelanoma skin cancer was identified in 5,750 (9.2%) participants via annual linkage to the Surveillance, Epidemiology, and End Results (SEER) cancer registry (6) . The remainders were censored at the earliest date of the following events: withdrawal from study (n ¼ 19), emigration from the SEER region (n ¼ 4,290), death (n ¼ 1,900), or December 31, 2008 (the date of complete case ascertainment at time of linkage to the SEER registry; n ¼ 50,882).
Statistical analysis
Cox proportional hazards models using participants' age as the time metric estimated HRs and 95% confidence intervals (95% CI) for the associations between acetaminophen use and incident malignancies. For analyses of individual tumor types, various cancer entities were treated as separate outcomes, and cases of other malignancies were censored at their respective time of diagnosis. P values for trend were computed by using the categorized 10-year acetaminophen use variable as ordinal in regression models. All reported P values are 2-sided, and P < 0.05 was considered statistically significant. 
Results
High
Discussion
In our study, there was no evidence for an association between acetaminophen use and total cancer risk overall A priori potential confounders were selected, including known and suspected cancer risk factors and medical conditions that may be indications for use of acetaminophen, for adjustment in multivariable regression models. Specifically, all models were adjusted for age, education, race, marital status, height, body mass index, physical activity, pack-years of smoking, alcohol intake at 45 years, fruit and vegetable intake, red meat intake, multivitamin use, self-rated health, family history of colon, lung, and hematologic cancers (as separate terms), sigmoidoscopy in the past 10 years, diabetes, osteoarthritis/chronic joint pain, migraine/chronic headaches, and use of nonsteroidal anti-inflammatory drugs. The models were additionally adjusted for family history of breast cancer, mammogram in the past 2 years, age at menarche, age at menopause, age at first birth, years of estrogen therapy, years of combined hormone therapy, and hysterectomy (for women); and family history of prostate cancer and prostate-specific antigen test in the past 2 years (for men). Besides cancers of colon/rectum and pancreas, contains cancers of esophagus (n ¼ 56), stomach (n ¼ 56), liver (n ¼ 47), small intestines (n ¼ 21), anus and anal canal (n ¼ 15), gall bladder (n ¼ 11), biliary tract (n ¼ 9), and other or ill-defined digestive organs (n ¼ 17).
d
All models were adjusted as described in footnote to Table 1 . 0.64 for aggressive subforms, there was no association with overall prostate cancer, although there was a statistically nonsignificant trend toward reduced risk for aggressive prostate cancer; this comparison may be limited given the differences in definition of acetaminophen use between the 2 studies.
Despite the large cohort size, however, our study had limited power in detecting associations between acetaminophen use and risk of individual cancers or cancer subtypes. Nonetheless, it is reassuring that we did not find an association between high acetaminophen use and specific cancers other than hematologic malignancies. The latter observation suggests a particular sensitivity of the hematopoietic system to acetaminophen. The reason for this predisposition is unclear and will deserve further study.
